UBS Group’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-77,500
Closed -$3.78M – 10786
2025
Q3
$3.78M Buy
+77,500
New +$4.8M ﹤0.01% 4330

Other funds holding HAE

UBS Group's HAE Position: Q3 2026 in Review

UBS Group increased its Haemonetics (HAE) stake by 14% in Q3 2026, buying an estimated $12.6M and bringing the position to 1,119,167 shares worth $118M. The position accounts for 0.02% of the portfolio, ranked #991.

UBS Group first reported a position in HAE in Q2 2013 and has held it in 54 quarters since. 361 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

  • UBS Group held 1,119,167 shares of Haemonetics worth $118M as of Q3 2026.
  • UBS Group bought 135,789 Haemonetics shares in Q3 2026, an estimated $12.6M.
  • Haemonetics made up 0.02% of UBS Group's portfolio in Q3 2026, its #991 holding.
  • UBS Group first reported a position in Haemonetics in Q2 2013 and has held it in 54 quarters since.
  • 361 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.